Peptides and Australian Law: Schedule Status of Every Research Peptide

Are research peptides legal in Australia?

Australian law gives no one-word answer, because three layers apply. Under the Therapeutic Goods Act 1989, peptide products are regulated as therapeutic goods (medicines and similar health products), and an unapproved peptide product is one the TGA (the Therapeutic Goods Administration, the national medicines regulator) has not included in the Australian Register of Therapeutic Goods (ARTG, the register that carries approved medicines) (TGA, 13 April 2026). Scheduling is the second layer: a named substance sits in a Schedule or it does not. State and territory laws are the third layer and may add controls on the sale, supply and possession of unapproved peptide products (TGA, 13 April 2026).

The same advisory says unapproved peptide products 'have not been evaluated for safety, quality or effectiveness by the TGA', and that a 'research use only' disclaimer does not make supply lawful (TGA, 13 April 2026). Those statements are about approval, not scheduling, and the two questions stay apart. The TGA names BPC-157 among its examples of unapproved peptide products, and the October 2026 edition of the Poisons Standard, a legal document called an instrument, gives BPC-157 an individual Schedule 4 entry. The TGA names retatrutide among the same examples, and no individual entry for retatrutide was found in the instrument.

Evidence limits

What can this page not tell you?

A Schedule entry is a classification, not a permission, and a missing entry is not a permission either. Section 7 of the instrument says that, unless a contrary intention appears, a reference to a substance includes 'every … derivative of the substance' and 'a preparation or admixture (a mixture) containing any proportion of the substance'. A derivative is a substance made by changing the original. A named entry can therefore reach more than the exact name, and a missing name does not settle what the group headings (class entries) cover.

New editions replace old ones: section 4(1) of the October 2026 instrument repeals the June 2026 edition. This page is meant to be re-read against each new edition, and the read date in the table shows which edition was last checked.

Which research peptides are in Schedule 4?

Schedule 4, headed 'Prescription only medicines and prescription animal remedies', holds BPC-157, CJC-1295 (named with CAS No. 863288-34-0), ipamorelin, TB-500 and tirzepatide as named entries in F2026L01327, the October 2026 instrument checked on 1 October 2026 (UTC). A CAS number is a registry number that identifies one chemical. The first four entries carry a # marker and also appear in Appendix D; tirzepatide's does not. For the other seven catalogue compounds, no Schedule 4 status is stated here: five have no individual entry found and two are held.

The table below quotes each entry text, with hyphens written as ordinary hyphens. The research guides set each compound in context: BPC-157, CJC-1295 with ipamorelin and TB-500.

The Form Laboratories catalogue sells CJC-1295 under the label 'No DAC'. The instrument names CJC-1295 with the CAS number above and does not use that label, so this page does not decide whether that form falls under the named entry.

What is Appendix D in the Poisons Standard?

Appendix D, clause 5 (a numbered part of the appendix), headed 'Poisons for which possession without authority is illegal', is a table in the Poisons Standard that, in the instrument's words, 'specifies poisons that must not be possessed by a person without authority (for example, possession other than in accordance with a legal prescription)'. An appendix is a table or list placed after the schedules in the instrument. The 1 October 2026 (UTC) reading of F2026L01327, the October edition, places BPC-157 at item 5, CJC-1295 at item 7, ipamorelin at item 25 and TB-500 at item 38.

Item numbers move between editions while the entry stays. TB-500 was item 35 in the June 2026 edition and is item 38 in the October 2026 edition, with the entry text unchanged (read 1 October 2026). That is why the table names the item and the edition together.

State and territory laws may add controls on possession (TGA, 13 April 2026), so the instrument alone does not settle any person's position, and this page does not try to.

Tirzepatide follows a different path. Its Schedule 4 entry has no # marker, so it has no Appendix D entry, and it appears in Appendix L, clause 2 ('Additional warning statements for certain human medicines'), item 41, which points to warning statement number 67 in Appendix F, clause 1. The warning text is not reproduced here.

What does 'no individual entry' mean?

'No individual entry' means the 1 October 2026 (UTC) search found no named entry in the October instrument F2026L01327. The search covered semax, selank, NAD+, MOTS-c and retatrutide, using each name plus variant spellings, spelled-out names and research codes (lab identifiers) where they exist. The result is not a statement that any of them is lawful, approved, free to possess or free to sell. It also does not show that no group heading applies, because section 7 reaches derivatives and preparations. Scheduling status and TGA approval are separate questions.

NAD+ is short for nicotinamide adenine dinucleotide. This coenzyme is a helper molecule that enzymes (proteins that speed up chemical reactions) rely on, and it is central to how cells turn food into energy (Covarrubias et al., 2021). NAD+ has a nucleotide structure, made of small chemical building blocks rather than an amino-acid chain (ChEBI, CHEBI:15846). The instrument has no entry under either name.

Can you import peptides into Australia?

The TGA publishes the conditions that apply when peptides are imported, and it states that a 'research use only' label does not permit importation (TGA, 13 April 2026). Under the Personal Importation Scheme, the TGA scheme for people importing goods for themselves or immediate family, goods not on the ARTG are covered only if all conditions are met. These include a valid Australian prescription or written authority when the medicine is prescription-only in Australia, and original or clearly identifying packaging (TGA, Personal Importation Scheme, last updated 8 September 2026). Poorly labelled vials will not be released under the scheme (TGA, 7 May 2026).

The scheme covers goods for the importer's own or immediate family's use, and they 'cannot be sold or supplied to any other person' (TGA, Personal Importation Scheme). The TGA says that where peptide products do not meet the requirements because of poor labelling, it will notify Australian Border Force (ABF) to seize and destroy them at the border (TGA, 7 May 2026).

No compound is tested against those conditions here. A parcel posted between two Australian addresses is not an import; the Perth ordering page covers that side, and state and territory laws may still add controls.

Are peptides banned in sport in Australia?

Many peptides are prohibited in sport under the World Anti-Doping Code, the international anti-doping rulebook, according to Sport Integrity Australia (SIA) in its statement of 13 May 2026. SIA lists BPC-157, CJC-1295, ipamorelin, MOTS-c and thymosin beta-4 (TB-500) among common examples (SIA, Peptides explained, page read 3 October 2026). Under Australia's strict-liability rules, athletes are accountable for any prohibited substance in their system, no matter the source (SIA, 13 May 2026). These are sport rules, separate from the Poisons Standard.

A Therapeutic Use Exemption (TUE) is an approval that can let an athlete use a prohibited medicine that a doctor prescribes. SIA says a TUE is 'unlikely to be granted for an unregistered medicine', and that the athlete may then face an anti-doping rule violation (ADRV) (SIA, Peptides explained). SIA points athletes to the Global DRO website, which shows the status of substances on the World Anti-Doping Agency (WADA) Prohibited List, and to the Sport Integrity App.

No sport statement is made here about any compound that those SIA pages do not name.